Raphael Brendan Merriman, MD
Gastroenterology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 7
Offices
7 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: California Pacific Medical Center- Van Ness Campus · Sutter Auburn Faith Hospital · Sutter Davis Hospital · Sutter Medical Center, Sacramento · Sutter Roseville Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Merriman’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A70327 · Current
Licensed to practise in California · since 1999 · expires 2027-10-31 · National University of Ireland University College at Dublin.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- Sutter Auburn Faith HospitalAuburn, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Sutter Davis HospitalDavis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 82% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Sutter Medical Center, SacramentoSacramento, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.9 (12 to 15.9) · 992 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.066, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.335, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.215, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.46, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.253, Oct 2024 – Sep 2025
- Sutter Roseville Medical CenterRoseville, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Pressure ulcer rate: 0.08 (0 to 0.56) · 12,400 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.069, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.262, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.128, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.357, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Sutter Auburn Faith Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0 to 2.01) · 312 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.62 to 1.46) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 160.66 (100.73 to 220.58) · 26 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.5 · 63 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.7 · 160 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16 · 241 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.6 · 105 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 1,272 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,484 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.08 to 0.5) · 2,442 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.11 (1.72 to 6.49) · 442 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 130 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.12 (0.47 to 3.78) · 417 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.72 (0.67 to 18.77) · 133 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.26 (4.11 to 12.4) · 113 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.18 to 3.18) · 135 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 1.3) · 1,845 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 34 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.2 · 215 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.9 · 178 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -30.1 · 250 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.1 · 300 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.5 to 8.5) · 58 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.6 (8 to 16.4) · 58 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 32 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 95 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.7 (9 to 15.2) · 1,787 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 473 cases | No different | Jan 2024 – Dec 2024 |
What patients said (563 patients answered, 27% of those asked)
| Cleanliness | 5 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 81% |
| Nurses "always" communicated well | 83% |
| Doctors "always" communicated well | 84% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 91% |
| Doctors "always" explained things so they could understand | 81% |
| Doctors "always" listened carefully | 82% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 80% |
| Nurses "always" listened carefully | 81% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sutter Davis Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 1 the same, 0 worse of 2 measures. Readmissions: 1 better, 7 the same, 0 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.07) · 247 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.43 to 1.32) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.7 · 28 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 151 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.1 · 91 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.9 · 94 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 857 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,791 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,822 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.22 (0.68 to 5.75) · 179 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (0.56 to 3.98) · 161 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.25) · 41 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.37 (0 to 1.4) · 1,424 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.351 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 169 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -13 · 94 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 123 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 34 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.6 to 16.4) · 878 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 240 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 82% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 91% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 82% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 80% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 82% |
| Staff "always" explained possible side effects | 55% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Sutter Medical Center, Sacramento
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.9 (12 to 15.9) · 992 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.066 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.335 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.215 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.46 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.253 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.12 (0.29 to 1.94) · 2,408 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.78 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.68 (126.66 to 206.71) · 180 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 292 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.8 · 543 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 425 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 5,216 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.11 (0 to 0.29) · 9,948 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.45) · 10,968 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.04 (1.53 to 4.56) · 3,983 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.33 (0.2 to 2.46) · 2,033 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.78 (1.69 to 3.87) · 3,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.79 (6.29 to 13.29) · 2,100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.62 (4.04 to 9.2) · 2,018 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.29 to 2.98) · 867 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.54 (0.07 to 1.01) · 8,613 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 294 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 598 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 924 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.5 · 488 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18.3 · 638 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.4 · 443 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 600 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.9 to 6.1) · 992 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 298 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 249 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.7 to 14.6) · 1,326 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 934 cases | No different | Jan 2024 – Dec 2024 |
What patients said (700 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Sutter Roseville Medical Center
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 5 better, 1 the same, 1 worse of 7 measures. Readmissions: 2 better, 7 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 0.08 (0 to 0.56) · 12,400 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.069 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.262 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.128 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.357 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.33 (0.49 to 2.17) · 2,916 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.63 to 1.17) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 147.2 (107.33 to 187.07) · 191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 250 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.7 · 484 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 839 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 1,027 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 656 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 6,822 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.08 to 0.42) · 14,300 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.06 to 0.41) · 14,490 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.43 (2.77 to 6.08) · 3,117 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0 to 2.95) · 938 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.06 (0.76 to 3.36) · 2,944 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.03 (2.8 to 15.25) · 840 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.43 (3.11 to 9.75) · 899 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.34 to 3.11) · 819 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 35 cases | None | Apr 2023 – Mar 2025 |
| SSI - Colon SurgeryInfections | 0.41 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 527 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 1,094 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -16.6 · 443 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -11 · 961 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8 · 1,064 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 1,293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.5 to 8.7) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (6.9 to 14.9) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.5 · 310 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.8 to 17.9) · 116 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 1,600 cases | No different | Jan 2024 – Dec 2024 |
What patients said (537 patients answered, 24% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$125,569
Medicare paid this office $125,569 for 399 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 160 | $33,670 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 78 | $30,968 | $104 |
| Long return visit (40+ min) | 91 | $22,802 | $124 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $9,202 | $153 |
| New patient visit (60+ min) | 47 | $8,297 | $177 |
See all 10 services
| Long return visit (40+ min) | 160 | $33,670 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 78 | $30,968 | $104 |
| Long return visit (40+ min) | 91 | $22,802 | $124 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $9,202 | $153 |
| New patient visit (60+ min) | 47 | $8,297 | $177 |
| Return visit (30+ min) | 55 | $6,038 | $86 |
| Critical care, first 30-74 minutes | 12 | $4,417 | $184 |
| Return visit (30+ min) | 24 | $3,321 | $81 |
| New patient visit (45+ min) | 14 | $1,587 | $113 |
| Measurement of liver stiffness | 16 | $429 | $27 |
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 1-10 | None |
Who their Medicare patients are
399 Original Medicare patients in 2024. Average age 69 · Women 49% · Also on Medicaid 38% · Health risk score 2.48. Sicker patients than 9 in 10 peers; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 74% · Diabetes 45% · Chronic kidney disease 44% · Coronary heart disease 26% · Depression 24% · Heart failure 18% · Atrial fibrillation 16% · COPD 13% · Cancer 12% · Dementia 7% · Stroke 5%.
The office billed $516,876, Medicare allowed $166,459 and paid $125,569; for 1,065 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 399 | 1,065 | 69 | 2.48 | $516,876 | $125,569 |
| 2023 | 407 | 1,174 | 69 | 2.77 | $545,029 | $138,425 |
| 2022 | 401 | 1,211 | 68 | 2.59 | $557,492 | $137,788 |
| 2021 | 403 | 1,202 | 69 | 2.49 | $538,234 | $142,729 |
| 2020 | 408 | 1,177 | 67 | 2.75 | $587,764 | $125,929 |
| 2019 | 398 | 1,090 | 67 | 2.68 | $519,725 | $112,957 |
| 2018 | 390 | 1,029 | 66 | 2.69 | $498,382 | $104,727 |
| 2017 | 353 | 945 | 66 | 2.67 | $451,698 | $91,904 |
| 2016 | 358 | 929 | 64 | 2.69 | $442,722 | $93,034 |
| 2015 | 372 | 921 | 65 | 2.76 | $449,067 | $97,049 |
| 2014 | 366 | 941 | 64 | 2.59 | $490,688 | $102,175 |
| 2013 | 167 | 319 | 64 | 2.28 | $157,324 | $35,295 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Long return visit (40+ min) | 162 | $35,537 | $136 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 70 | $34,865 | $108 |
| Long return visit (40+ min) | 108 | $24,298 | $123 |
| Critical care, first 30-74 minutes | 13 | $9,474 | $189 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 53 | $8,800 | $157 |
| Return visit (30+ min) | 53 | $6,692 | $97 |
| New patient visit (60+ min) | 29 | $4,271 | $147 |
| Return visit (30+ min) | 31 | $3,376 | $79 |
| New patient visit (60+ min) | 13 | $2,136 | $164 |
| New patient visit (45+ min) | 15 | $1,881 | $125 |
| Measurement of liver stiffness | 21 | $523 | $25 |
2022: 9 services
| Long return visit (40+ min) | 171 | $36,616 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 69 | $32,635 | $93 |
| Long return visit (40+ min) | 122 | $29,587 | $117 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $9,607 | $178 |
| Critical care, first 30-74 minutes | 12 | $7,502 | $192 |
| Return visit (30+ min) | 48 | $5,774 | $95 |
| New patient visit (60+ min) | 31 | $4,474 | $144 |
| Return visit (30+ min) | 39 | $4,155 | $80 |
| New patient visit (45+ min) | 11 | $1,119 | $102 |
2021: 9 services
| Long return visit (40+ min) | 149 | $39,532 | $127 |
| Long return visit (40+ min) | 160 | $37,702 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $26,054 | $93 |
| Critical care, first 30-74 minutes | 16 | $9,379 | $195 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,421 | $181 |
| New patient visit (60+ min) | 34 | $5,558 | $163 |
| Return visit (30+ min) | 36 | $4,351 | $76 |
| Return visit (30+ min) | 34 | $3,646 | $89 |
| Telephone medical discussion with physician, 21-30 minutes | 31 | $3,637 | $87 |
2020: 11 services
| Long return visit (40+ min) | 186 | $33,856 | $107 |
| Long return visit (40+ min) | 141 | $28,188 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 69 | $26,734 | $94 |
| Critical care, first 30-74 minutes | 21 | $11,368 | $196 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,622 | $184 |
| New patient visit (60+ min) | 35 | $5,550 | $159 |
| New patient visit (60+ min) | 22 | $3,418 | $155 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | $2,545 | $88 |
| Return visit (30+ min) | 24 | $2,120 | $79 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | $1,874 | $69 |
| Return visit (30+ min) | 15 | $1,037 | $58 |
2019: 10 services
| Long return visit (40+ min) | 212 | $40,635 | $110 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $28,207 | $94 |
| Long return visit (40+ min) | 85 | $18,365 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $7,111 | $182 |
| Critical care, first 30-74 minutes | 12 | $4,334 | $197 |
| New patient visit (60+ min) | 22 | $3,656 | $166 |
| Return visit (30+ min) | 29 | $2,432 | $74 |
| New patient visit (60+ min) | 15 | $2,270 | $151 |
| Return visit (30+ min) | 21 | $1,895 | $70 |
| Measurement of liver stiffness | 32 | $897 | $28 |
2018: 10 services
| Long return visit (40+ min) | 185 | $33,808 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 68 | $24,175 | $90 |
| Long return visit (40+ min) | 52 | $9,632 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $8,033 | $175 |
| New patient visit (60+ min) | 32 | $5,074 | $159 |
| Return visit (30+ min) | 48 | $4,268 | $74 |
| New patient visit (60+ min) | 19 | $2,746 | $145 |
| Return visit (30+ min) | 25 | $2,127 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,757 | $63 |
| Measurement of liver stiffness | 18 | $487 | $26 |
2017: 13 services
| Long return visit (40+ min) | 149 | $28,847 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $17,640 | $90 |
| Long return visit (40+ min) | 68 | $11,236 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,024 | $174 |
| New patient visit (60+ min) | 31 | $4,591 | $148 |
| Return visit (30+ min) | 43 | $3,094 | $70 |
| New patient visit (60+ min) | 21 | $2,913 | $139 |
| Return visit (30+ min) | 28 | $2,205 | $61 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,436 | $96 |
| New patient visit (45+ min) | 11 | $1,169 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,066 | $63 |
| Measurement of liver stiffness | 19 | $517 | $27 |
| Measurement of liver stiffness | 19 | $218 | $11 |
2016: 11 services
| Long return visit (40+ min) | 186 | $32,844 | $107 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 57 | $25,105 | $91 |
| Long return visit (40+ min) | 63 | $8,720 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $6,222 | $178 |
| New patient visit (60+ min) | 26 | $4,163 | $160 |
| New patient visit (60+ min) | 12 | $1,724 | $144 |
| Return visit (30+ min) | 22 | $1,643 | $75 |
| Return visit (30+ min) | 19 | $1,249 | $62 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,194 | $109 |
| Measurement of liver stiffness | 33 | $823 | $24 |
| Measurement of liver stiffness | 12 | $141 | $11 |
2015: 11 services
| Long return visit (40+ min) | 177 | $31,777 | $107 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $24,462 | $93 |
| Long return visit (40+ min) | 64 | $10,029 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $8,803 | $180 |
| New patient visit (60+ min) | 29 | $4,553 | $157 |
| New patient visit (60+ min) | 18 | $2,719 | $151 |
| Return visit (30+ min) | 31 | $2,630 | $82 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,333 | $111 |
| New patient visit (45+ min) | 12 | $1,256 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,236 | $65 |
| Return visit (30+ min) | 17 | $1,131 | $67 |
2014: 11 services
| Long return visit (40+ min) | 181 | $35,401 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 68 | $24,278 | $93 |
| Long return visit (40+ min) | 73 | $10,507 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 45 | $8,126 | $177 |
| Critical care, first 30-74 minutes | 12 | $5,098 | $196 |
| New patient visit (60+ min) | 26 | $4,350 | $167 |
| Return visit (30+ min) | 28 | $2,480 | $77 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 18 | $2,341 | $117 |
| New patient visit (60+ min) | 15 | $2,124 | $142 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $1,930 | $64 |
| Return visit (30+ min) | 15 | $1,124 | $66 |
2013: 5 services
| Long return visit (40+ min) | 98 | $14,401 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $8,250 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,596 | $173 |
| New patient visit (60+ min) | 13 | $2,181 | $168 |
| Return visit (30+ min) | 17 | $1,505 | $89 |
Medicaid work
$35,447 in 2024
Medicaid paid $35,447 for 597 billed services this clinician did in 2024, up to 29 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 385 | $21,605 |
| Long return visit (40+ min) | 212 | $13,842 |
| 2024 | 597 | 2 | 29 | $35,447 |
| 2023 | 641 | 3 | 33 | $28,489 |
| 2022 | 535 | 2 | 32 | $26,310 |
| 2021 | 535 | 2 | 33 | $25,241 |
| 2020 | 506 | 2 | 37 | $18,765 |
| 2019 | 321 | 2 | 21 | $17,423 |
| 2018 | 294 | 2 | 24 | $18,801 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 360 | $13,867 |
| Long return visit (40+ min) | 241 | $13,119 |
| Return visit (30+ min) | 40 | $1,503 |
2022
| Long return visit (40+ min) | 280 | $13,861 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 255 | $12,449 |
2021
| Long return visit (40+ min) | 296 | $13,273 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 239 | $11,968 |
2020
| Long return visit (40+ min) | 344 | $11,319 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 162 | $7,446 |
2019
| Long return visit (40+ min) | 168 | $10,180 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 153 | $7,243 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 213 | $11,375 |
| Long return visit (40+ min) | 81 | $7,427 |
Drugs they prescribed that Part D paid
$916,799
Pharmacies billed $916,799 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (11 of 1,662) in 2024. A higher opioid share than 9 in 10 peers; the typical gastroenterology clinician is at 0%.
1,310 generic and fewer than 11 brand-name prescriptions · $916,799 in drug cost · 201 antibiotic prescriptions to 44 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xifaxan | 111 | $438,059 | $3,946 |
| Vemlidy | 120 | $210,168 | $1,751 |
| Entecavir | 92 | $38,938 | $423 |
| Veltassa | 23 | $34,155 | $1,485 |
| Tenofovir Disoproxil | 62 | $30,693 | $495 |
See all 30 drugs
| Xifaxan | 111 | $438,059 | $3,946 |
| Vemlidy | 120 | $210,168 | $1,751 |
| Entecavir | 92 | $38,938 | $423 |
| Veltassa | 23 | $34,155 | $1,485 |
| Tenofovir Disoproxil | 62 | $30,693 | $495 |
| Ursodiol | 127 | $26,444 | $208 |
| Tacrolimus | 151 | $23,293 | $154 |
| Eliquis | 13 | $8,436 | $649 |
| Valganciclovir | 27 | $6,060 | $224 |
| Mycophenolic Acid | 23 | $4,926 | $214 |
| Enulose | 36 | $4,598 | $128 |
| Mycophenolate Mofetil | 46 | $4,462 | $97 |
| Lactulose | 52 | $2,637 | $51 |
| Budesonide Ec | 11 | $1,955 | $178 |
| Azathioprine | 43 | $1,911 | $44 |
| Spironolactone | 98 | $1,650 | $17 |
| Budesonide Dr | 11 | $1,186 | $108 |
| Fluconazole | 30 | $985 | $33 |
| Constulose | 13 | $670 | $52 |
| Prednisone | 77 | $589 | $8 |
| Furosemide | 101 | $554 | $5 |
| Sulfamethoxazole-Trimethoprim | 55 | $421 | $8 |
| Pantoprazole | 33 | $333 | $10 |
| Megestrol Acetate | 12 | $288 | $24 |
| Propranolol | 12 | $151 | $13 |
| Omeprazole | 11 | $139 | $13 |
| Ciprofloxacin | 17 | $134 | $8 |
| Carvedilol | 27 | $97 | $4 |
| Metoprolol | 17 | $95 | $6 |
| Amlodipine Besylate | 17 | $29 | $2 |
Year by year
| 2024 | 1,662 | 247 | 1% (11) | None | $916,799 |
| 2023 | 1,587 | 244 | 1% (15) | 20% | $851,565 |
| 2022 | 1,539 | 210 | None | 24% | $1,036,858 |
| 2021 | 1,671 | 217 | 1% (16) | 21% | $928,815 |
| 2020 | 1,566 | 202 | 2% (28) | None | $902,629 |
| 2019 | 1,375 | 180 | 1% (15) | 21% | $747,083 |
| 2018 | 1,099 | 140 | None | 24% | $1,261,724 |
| 2017 | 1,036 | 143 | 2% (16) | 37% | $1,610,684 |
| 2016 | 1,164 | 151 | 2% (18) | None | $3,381,660 |
| 2015 | 1,338 | 170 | 3% (35) | None | $4,968,258 |
| 2014 | 931 | 137 | 3% (28) | None | $2,875,708 |
| 2013 | 175 | 48 | None | 42% | $105,604 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 26 drugs
| Xifaxan | 75 | $325,551 | $4,341 |
| Vemlidy | 133 | $234,490 | $1,763 |
| Tenofovir Disoproxil | 76 | $48,662 | $640 |
| Entecavir | 96 | $46,581 | $485 |
| Ursodiol | 111 | $30,186 | $272 |
| Tacrolimus | 141 | $26,928 | $191 |
| Veltassa | 21 | $26,250 | $1,250 |
| Eliquis | 22 | $12,350 | $561 |
| Valganciclovir | 20 | $11,227 | $561 |
| Mycophenolate Mofetil | 56 | $7,506 | $134 |
| Mycophenolic Acid | 19 | $3,960 | $208 |
| Lactulose | 57 | $3,232 | $57 |
| Azathioprine | 51 | $2,678 | $53 |
| Spironolactone | 101 | $2,479 | $25 |
| Enulose | 11 | $1,553 | $141 |
| Pantoprazole | 40 | $898 | $22 |
| Constulose | 11 | $857 | $78 |
| Furosemide | 82 | $734 | $9 |
| Prednisone | 78 | $710 | $9 |
| Fluconazole | 22 | $621 | $28 |
| Propranolol | 22 | $450 | $20 |
| Sulfamethoxazole-Trimethoprim | 56 | $443 | $8 |
| Ondansetron | 23 | $438 | $19 |
| Metoprolol | 19 | $316 | $17 |
| Ciprofloxacin | 22 | $229 | $10 |
| Metronidazole | 14 | $95 | $7 |
2022: 29 drugs
| Xifaxan | 89 | $300,956 | $3,382 |
| Vemlidy | 135 | $222,423 | $1,648 |
| Entecavir | 96 | $49,860 | $519 |
| Valganciclovir | 24 | $42,566 | $1,774 |
| Ursodiol | 122 | $40,378 | $331 |
| Tenofovir Disoproxil | 76 | $33,650 | $443 |
| Tacrolimus | 143 | $22,149 | $155 |
| Veltassa | 11 | $17,470 | $1,588 |
| Eliquis | 17 | $9,815 | $577 |
| Novolog Flexpen | 12 | $6,334 | $528 |
| Lactulose | 51 | $5,309 | $104 |
| Mycophenolate Mofetil | 52 | $4,510 | $87 |
| Azathioprine | 36 | $3,024 | $84 |
| Spironolactone | 70 | $2,477 | $35 |
| Budesonide Ec | 17 | $2,383 | $140 |
| Fluconazole | 26 | $1,588 | $61 |
| Nano 2nd Gen Pen Needle | 18 | $971 | $54 |
| Constulose | 18 | $948 | $53 |
| Furosemide | 99 | $786 | $8 |
| Prednisone | 64 | $715 | $11 |
| Pantoprazole | 40 | $539 | $13 |
| Omeprazole | 20 | $314 | $16 |
| Ondansetron | 11 | $238 | $22 |
| Sulfamethoxazole-Trimethoprim | 49 | $234 | $5 |
| Propranolol | 17 | $214 | $13 |
| Ciprofloxacin | 14 | $208 | $15 |
| Levothyroxine | 14 | $196 | $14 |
| Metoprolol | 11 | $129 | $12 |
| Amlodipine Besylate | 23 | $90 | $4 |
2021: 30 drugs
| Xifaxan | 119 | $368,350 | $3,095 |
| Vemlidy | 76 | $116,697 | $1,535 |
| Entecavir | 119 | $48,402 | $407 |
| Valganciclovir | 35 | $35,048 | $1,001 |
| Ursodiol | 118 | $33,393 | $283 |
| Tacrolimus | 128 | $18,410 | $144 |
| Sirolimus | 18 | $16,486 | $916 |
| Tenofovir Disoproxil | 93 | $13,558 | $146 |
| Eliquis | 12 | $6,312 | $526 |
| Mycophenolate Mofetil | 62 | $5,729 | $92 |
| Lactulose | 62 | $3,476 | $56 |
| Spironolactone | 79 | $3,008 | $38 |
| Azathioprine | 38 | $2,670 | $70 |
| Enulose | 14 | $2,412 | $172 |
| Lantus Solostar | 12 | $2,326 | $194 |
| Constulose | 14 | $2,137 | $153 |
| Fluconazole | 29 | $1,315 | $45 |
| Nano 2nd Gen Pen Needle | 22 | $1,128 | $51 |
| Propranolol | 33 | $891 | $27 |
| Pantoprazole | 77 | $767 | $10 |
| Furosemide | 106 | $720 | $7 |
| Prednisone | 41 | $475 | $12 |
| Sulfamethoxazole-Trimethoprim | 52 | $300 | $6 |
| Omeprazole | 18 | $276 | $15 |
| Ondansetron | 16 | $227 | $14 |
| Doxepin | 14 | $191 | $14 |
| Ciprofloxacin | 16 | $178 | $11 |
| Amiloride | 13 | $85 | $7 |
| Metronidazole | 13 | $72 | $6 |
| Amlodipine Besylate | 22 | $70 | $3 |
2020: 25 drugs
| Xifaxan | 117 | $323,402 | $2,764 |
| Vemlidy | 59 | $87,699 | $1,486 |
| Ursodiol | 118 | $45,519 | $386 |
| Entecavir | 120 | $36,946 | $308 |
| Tenofovir Disoproxil | 125 | $23,292 | $186 |
| Tacrolimus | 84 | $22,275 | $265 |
| Valganciclovir | 30 | $17,002 | $567 |
| Sirolimus | 16 | $15,267 | $954 |
| Mycophenolate Mofetil | 56 | $5,317 | $95 |
| Lactulose | 51 | $4,314 | $85 |
| Spironolactone | 112 | $3,455 | $31 |
| Enulose | 15 | $3,411 | $227 |
| Azathioprine | 31 | $2,302 | $74 |
| Fluconazole | 25 | $1,805 | $72 |
| Constulose | 11 | $1,504 | $137 |
| Propranolol | 46 | $1,106 | $24 |
| Furosemide | 120 | $697 | $6 |
| Prednisone | 57 | $599 | $11 |
| Pantoprazole | 56 | $577 | $10 |
| Ondansetron | 22 | $385 | $17 |
| Sulfamethoxazole-Trimethoprim | 39 | $341 | $9 |
| Omeprazole | 16 | $273 | $17 |
| Ciprofloxacin | 26 | $229 | $9 |
| Metronidazole | 21 | $137 | $7 |
| Hydrocodone-Acetaminophen | 19 | $109 | $6 |
2019: 25 drugs
| Xifaxan | 105 | $258,214 | $2,459 |
| Ursodiol | 74 | $36,252 | $490 |
| Vemlidy | 26 | $36,239 | $1,394 |
| Tacrolimus | 112 | $21,959 | $196 |
| Truvada | 12 | $20,905 | $1,742 |
| Valganciclovir | 17 | $20,629 | $1,213 |
| Entecavir | 85 | $18,481 | $217 |
| Sirolimus | 20 | $16,792 | $840 |
| Tenofovir Disoproxil | 105 | $15,204 | $145 |
| Mycophenolate Mofetil | 50 | $5,090 | $102 |
| Spironolactone | 136 | $2,587 | $19 |
| Azathioprine | 35 | $2,428 | $69 |
| Lactulose | 19 | $770 | $41 |
| Furosemide | 140 | $738 | $5 |
| Ultra-Fine Nano Pen Needle | 15 | $720 | $48 |
| Fluconazole | 19 | $614 | $32 |
| Pantoprazole | 45 | $577 | $13 |
| Generlac | 15 | $491 | $33 |
| Propranolol | 39 | $475 | $12 |
| Prednisone | 52 | $331 | $6 |
| Ciprofloxacin | 27 | $243 | $9 |
| Ondansetron | 21 | $168 | $8 |
| Metronidazole | 20 | $129 | $6 |
| Hydrocodone-Acetaminophen | 11 | $84 | $8 |
| Sulfamethoxazole-Trimethoprim | 20 | $77 | $4 |
2018: 19 drugs
| Harvoni | 13 | $399,562 | $30,736 |
| Mavyret | 19 | $249,943 | $13,155 |
| Xifaxan | 74 | $158,571 | $2,143 |
| Entecavir | 99 | $68,742 | $694 |
| Truvada | 27 | $45,846 | $1,698 |
| Tenofovir Disoproxil | 91 | $45,220 | $497 |
| Ursodiol | 62 | $27,316 | $441 |
| Valganciclovir | 13 | $22,821 | $1,755 |
| Tacrolimus | 125 | $17,522 | $140 |
| Mycophenolate Mofetil | 38 | $2,562 | $67 |
| Azathioprine | 38 | $2,106 | $55 |
| Spironolactone | 79 | $1,234 | $16 |
| Nadolol | 11 | $1,220 | $111 |
| Prednisone | 47 | $462 | $10 |
| Furosemide | 116 | $390 | $3 |
| Lactulose | 21 | $376 | $18 |
| Pantoprazole | 39 | $341 | $9 |
| Propranolol | 25 | $338 | $14 |
| Ciprofloxacin | 18 | $176 | $10 |
2017: 26 drugs
| Harvoni | 11 | $354,734 | $32,249 |
| Xifaxan | 87 | $172,326 | $1,981 |
| Viread | 103 | $134,100 | $1,302 |
| Entecavir | 75 | $56,879 | $758 |
| Valganciclovir | 23 | $49,970 | $2,173 |
| Truvada | 24 | $38,033 | $1,585 |
| Ursodiol | 57 | $24,727 | $434 |
| Tacrolimus | 135 | $18,590 | $138 |
| Mycophenolate Mofetil | 30 | $14,768 | $492 |
| Mycophenolic Acid | 14 | $8,549 | $611 |
| Sirolimus | 11 | $2,103 | $191 |
| Nadolol | 21 | $1,563 | $74 |
| Ribavirin | 11 | $1,441 | $131 |
| Spironolactone | 52 | $1,286 | $25 |
| Azathioprine | 16 | $1,028 | $64 |
| Lactulose | 30 | $898 | $30 |
| Constulose | 12 | $430 | $36 |
| Pantoprazole | 26 | $310 | $12 |
| Propranolol | 11 | $229 | $21 |
| Ciprofloxacin | 26 | $208 | $8 |
| Furosemide | 59 | $181 | $3 |
| Prednisone | 24 | $154 | $6 |
| Ondansetron | 11 | $100 | $9 |
| Metronidazole | 12 | $89 | $7 |
| Sulfamethoxazole-Trimethoprim | 17 | $88 | $5 |
| Amlodipine Besylate | 11 | $49 | $4 |
2016: 28 drugs
| Harvoni | 35 | $1,102,094 | $31,488 |
| Sovaldi | 25 | $691,071 | $27,643 |
| Epclusa | 13 | $329,117 | $25,317 |
| Zepatier | 15 | $270,719 | $18,048 |
| Daklinza | 12 | $250,592 | $20,883 |
| Xifaxan | 107 | $199,985 | $1,869 |
| Viread | 104 | $109,116 | $1,049 |
| Entecavir | 65 | $65,800 | $1,012 |
| Truvada | 24 | $35,868 | $1,495 |
| Valganciclovir | 14 | $33,035 | $2,360 |
| Ursodiol | 46 | $20,739 | $451 |
| Tacrolimus | 114 | $14,541 | $128 |
| Ribavirin | 34 | $8,647 | $254 |
| Sirolimus | 14 | $5,383 | $384 |
| Mycophenolate Mofetil | 46 | $4,166 | $91 |
| Spironolactone | 55 | $1,159 | $21 |
| Azathioprine | 22 | $1,096 | $50 |
| Lactulose | 20 | $636 | $32 |
| Furosemide | 72 | $402 | $6 |
| Generlac | 11 | $401 | $36 |
| Prednisone | 29 | $353 | $12 |
| Pantoprazole | 20 | $257 | $13 |
| Omeprazole | 24 | $235 | $10 |
| Ondansetron | 15 | $157 | $10 |
| Ciprofloxacin | 26 | $136 | $5 |
| Hydrocodone-Acetaminophen | 11 | $133 | $12 |
| Sulfamethoxazole-Trimethoprim | 33 | $119 | $4 |
| Metronidazole | 13 | $103 | $8 |
2015: 30 drugs
| Harvoni | 124 | $3,922,948 | $31,637 |
| Sovaldi | 12 | $333,848 | $27,821 |
| Xifaxan | 87 | $148,716 | $1,709 |
| Viread | 86 | $100,188 | $1,165 |
| Valganciclovir | 34 | $98,835 | $2,907 |
| Entecavir | 44 | $49,587 | $1,127 |
| Baraclude | 29 | $35,484 | $1,224 |
| Ursodiol | 38 | $23,713 | $624 |
| Truvada | 13 | $17,662 | $1,359 |
| Tacrolimus | 67 | $12,182 | $182 |
| Actigall | 12 | $10,533 | $878 |
| Ribavirin | 42 | $8,463 | $202 |
| Mycophenolate Mofetil | 32 | $2,273 | $71 |
| Spironolactone | 67 | $1,654 | $25 |
| Azathioprine | 23 | $1,266 | $55 |
| Nystatin | 13 | $1,066 | $82 |
| Lactulose | 19 | $793 | $42 |
| Warfarin | 23 | $375 | $16 |
| Pantoprazole | 39 | $370 | $9 |
| Ondansetron | 13 | $362 | $28 |
| Furosemide | 76 | $299 | $4 |
| Metoprolol | 47 | $294 | $6 |
| Omeprazole | 46 | $277 | $6 |
| Prednisone | 18 | $268 | $15 |
| Ciprofloxacin | 28 | $200 | $7 |
| Sulfamethoxazole-Trimethoprim | 54 | $191 | $4 |
| Metronidazole | 21 | $185 | $9 |
| Amlodipine Besylate | 36 | $162 | $4 |
| Hydrocodone-Acetaminophen | 19 | $146 | $8 |
| Tramadol | 14 | $73 | $5 |
2014: 26 drugs
| Sovaldi | 61 | $1,663,528 | $27,271 |
| Olysio | 30 | $609,628 | $20,321 |
| Xifaxan | 84 | $116,449 | $1,386 |
| Valcyte | 12 | $46,434 | $3,870 |
| Viread | 30 | $35,739 | $1,191 |
| Baraclude | 31 | $30,202 | $974 |
| Truvada | 12 | $15,730 | $1,311 |
| Ursodiol | 25 | $9,690 | $388 |
| Entecavir | 11 | $9,188 | $835 |
| Tacrolimus | 57 | $8,544 | $150 |
| Ribavirin | 30 | $7,390 | $246 |
| Rapamune | 15 | $6,343 | $423 |
| Nexium | 11 | $2,666 | $242 |
| Lactulose | 25 | $1,184 | $47 |
| Mycophenolate Mofetil | 11 | $993 | $90 |
| Spironolactone | 37 | $897 | $24 |
| Lansoprazole | 12 | $572 | $48 |
| Furosemide | 71 | $386 | $5 |
| Pantoprazole | 30 | $286 | $10 |
| Omeprazole | 29 | $268 | $9 |
| Metronidazole | 25 | $239 | $10 |
| Ciprofloxacin | 24 | $162 | $7 |
| Hydrocodone-Acetaminophen | 15 | $134 | $9 |
| Prednisone | 13 | $128 | $10 |
| Metoprolol | 21 | $124 | $6 |
| Sulfamethoxazole-Trimethoprim | 12 | $34 | $3 |
2013: 5 drugs
| Xifaxan | 28 | $31,874 | $1,138 |
| Viread | 14 | $15,050 | $1,075 |
| Spironolactone | 12 | $332 | $28 |
| Omeprazole | 13 | $143 | $11 |
| Furosemide | 13 | $66 | $5 |
Money from drug and device companies
$112 in 2025
| 2025 | 1 | 1 | None | $112 |
| 2023 | 1 | 1 | None | $105 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Cook Medical | Echotip Insight | $112 | 1 payment
|
See the published payment
| Cook Medical | Meals · 2025-07-17 | Echotip Insight | $112 |
See earlier years (2023)
2023: $105
| Djo | Donjoy | $105 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Intercept Pharmaceuticals, Inc. · Ocaliva · 2020 | Their institution | $53,267 |
| Intercept Pharmaceuticals, Inc. · Randomized Global Phase 3 Study To Evaluate the Impact on Nash With Fibrosis of Obeticholic Acid Treatment (Regenerate) · 2021 | Their institution | $52,843 |
| Intercept Pharma Europe Ltd. · Randomized Global Phase 3 Study To Evaluate the Impact on Nash With Fibrosis of Obeticholic Acid Treatment (Regenerate) · 2024 | Their institution | $43,870 |
| Intercept Pharmaceuticals, Inc. · Ocaliva · 2019 | Their institution | $40,657 |
| Gilead Sciences, Inc. · Stellar-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Nonalcoholic Steatohepatitis (Nash) and Bridging (F3) Fibrosis · 2019 | Their institution | $26,684 |
| Intercept Pharma Europe Ltd. · Randomized Global Phase 3 Study To Evaluate the Impact on Nash With Fibrosis of Obeticholic Acid Treatment (Regenerate) · 2023 | Their institution | $20,922 |
| Intercept Pharmaceuticals, Inc. · Randomized Global Phase 3 Study To Evaluate the Impact on Nash With Fibrosis of Obeticholic Acid Treatment (Regenerate) · 2022 | Their institution | $15,244 |
| Gilead Sciences, Inc. · Stellar-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due To Nonalcoholic Steatohepatitis (Nash) · 2020 | Their institution | $10,303 |
| Gilead Sciences, Inc. · Stellar-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Nonalcoholic Steatohepatitis (Nash) and Bridging (F3) Fibrosis · 2020 | Their institution | $9,553 |
| Gilead Sciences, Inc. · Stellar-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due To Nonalcoholic Steatohepatitis (Nash) · 2019 | Their institution | $6,428 |
| Gilead Sciences, Inc. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, Gs-0976, Gs-9674, and Combinations in Subjects With Bridging (F3) Fibrosis Or Compensated Cirrhosis (F4) Due To Nonalcoholic Steatohepatitis (Nash) · 2021 | Their institution | $3,750 |
| Intercept Pharmaceuticals, Inc. · Randomized Global Phase 3 Study To Evaluate the Impact on Nash With Fibrosis of Obeticholic Acid Treatment (Regenerate) · 2023 | Their institution | $2,415 |
Professional record
- NPI
- 1942258728
- Licence
- CA 070327California A70327: Current · expires 2027-10-31
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 0H4165600
- Taxonomy
- Federal specialty code 207RT0003X (207RT0003X); Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2006-05-04
- NPI last updated
- 2022-10-28
- NPI record certified
- 2022-10-28
This is when the NPI record was last certified, not a medical board exam.